Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$239.05 USD

239.05
718,021

+4.67 (1.99%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $239.04 -0.01 (0.00%) 7:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks News

LabCorp (LH) Q4 Earnings and Revenues Beat Estimates

LabCorp (LH) delivered earnings and revenue surprises of 14.75% and 2.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH

Medical device companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BIO, DXCM, and LH are poised ahead of their earnings releases.

Why Earnings Season Could Be Great for Laboratory Corporation (LH)

Laboratory Corporation (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cerner (CERN) to Report Q4 Earnings: What's in the Offing?

Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Doximity (DOCS) to Report Q3 Earnings: What's in the Cards?

Doximity's (DOCS) fiscal third-quarter results are likely to reflect growth in its telehealth platform and robust net revenue retention rate.

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) Q4 top line.

LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medtronic (MDT) Cardiovascular Line Rebounds, Spine Stays Soft

Medtronic (MDT) is registering organic growth in the Cardiovascular, Neuroscience and Diabetes segments.

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab.

Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Down

Impressive performance by Hologic's (HOLX) Breast Imaging and Interventional Breast Solutions drove Q1 revenues.

What's in Store for Canopy Growth (CGC) in Q3 Earnings?

New product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to drive Canopy Growth's (CGC) Q3 top line.

Quest Diagnostics (DGX) Q4 Revenues Top Estimates, Margins Down

Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.

Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Down

Robust segmental growth and iTero sales are driving Align Technology's (ALGN) Q4 top line.

Align Technology (ALGN) Surpasses Q4 Earnings and Revenue Estimates

Align Technology (ALGN) delivered earnings and revenue surprises of 6.39% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Gains But Lags Market: What You Should Know

LabCorp (LH) closed at $273.18 in the latest trading session, marking a +0.08% move from the prior day.

Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down

Thermo Fisher's (TMO) Q4 earnings surpassed the Zacks Consensus Estimate with strength across the Analytical Instruments segment driving the top line.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up

Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.

Here's Why You Should Retain West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.

Diagnostics Sales to Drive Hologic's (HOLX) Q1 Earnings

Strength in the Diagnostics division is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.

Zacks.com featured highlights include: Crocs, Laboratory Corp. of America, CBRE Group, Tesla and AGCO

Crocs, Laboratory Corp. of America, CBRE Group, Tesla and AGCO are included in this blog.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.

Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat

Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.